QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
Public ClinicalTrials.gov record NCT03228667. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
QUILT-3.055: A Phase IIb, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors
Study identification
- NCT ID
- NCT03228667
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- ImmunityBio, Inc.
- Industry
- Enrollment
- 40 participants
Conditions and interventions
Conditions
Not listed
Interventions
Not listed
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 10, 2018
- Primary completion
- Aug 30, 2029
- Completion
- Dec 30, 2030
- Last update posted
- Jan 13, 2026
2018 – 2030
United States locations
- U.S. sites
- 16
- U.S. states
- 9
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alaska Clinical Research Center | Anchorage | Alaska | 99530 | — |
| Genesis Cancer Center | Hot Springs | Arkansas | 71913 | — |
| Chan Soon-Shiong Institute for Medicine | El Segundo | California | 90245 | — |
| MemorialCare Health System | Fountain Valley | California | 37846 | — |
| Glendale Adventist Medical Center | Glendale | California | 91206 | — |
| University of Southern California Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
| Desert Hematology Oncology Medical Group, Inc. | Rancho Mirage | California | 92270 | — |
| Memorial Healthcare System | Hollywood | Florida | 33021 | — |
| Miami Cancer Institute (Baptist Health South Florida) | Miami | Florida | 33176 | — |
| University of Miami | Miami | Florida | 33180 | — |
| Horizon Oncology Associates | Lafayette | Indiana | 47905 | — |
| University of Iowa Holden Comprehensive Cancer Center | Iowa City | Iowa | 52242 | — |
| Baptist Health - Lexington | Lexington | Kentucky | 40503 | — |
| Baptist Health- Louisville | Louisville | Kentucky | 40207 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Henry Ford Hospital | Detroit | Michigan | 48202 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03228667, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 13, 2026 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03228667 live on ClinicalTrials.gov.